AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Condition(s):AngiosarcomaLast Updated:January 11, 2022Withdrawn
Hide Studies Not Open or Pending
Condition(s):AngiosarcomaLast Updated:January 11, 2022Withdrawn
Condition(s):Metastatic Soft Tissue Sarcoma; Advanced Soft Tissue SarcomaLast Updated:December 21, 2023Recruiting
Condition(s):Cervical CancerLast Updated:July 5, 2023Completed
Condition(s):Cervical CancerLast Updated:March 25, 2024Active, not recruiting
Condition(s):Urinary Bladder NeoplasmsLast Updated:March 28, 2022Unknown status
Condition(s):Advanced Cancer; Cervical CancerLast Updated:June 5, 2023Completed
Condition(s):CancerLast Updated:March 25, 2024Available
Condition(s):Refractory Metastatic Colorectal Cancer; Solid Tumor; Metastatic Microsatellite-stable Colorectal Cancer; Mismatch Repair Protein ProficientLast Updated:March 29, 2023Active, not recruiting
Condition(s):Metastatic Colorectal CancerLast Updated:March 25, 2024Active, not recruiting
Condition(s):Pancreatic Cancer Metastatic; Pancreatic Adenocarcinoma MetastaticLast Updated:October 11, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.